Drugs / GM-CSF DNA
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT00580060 | Dec 2003 → Jun 2011 | melanoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GM-CSF DNA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00580060 ↗ |
| Modality | Other / unclassified | “GM-CSF DNA as an adjuvant for peptide vaccination” NCT00580060 ↗ |
| Route | Subcutaneous | “GM-CSF DNA delivered subcutaneously” NCT00580060 ↗ |